SSSapna Syngal

Sapna Syngal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sapna Syngal has a total of 444 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Increased Prevalence of Pancreatic Cysts in Nonsecretor (Fut2-Null) Individuals under Pancreatic Surveillance

    by Yuto Hozaka, Masataka Hayashi, Emy Abou Sleiman, Bryson W. Katona, Randall E. Brand, Sapna Syngal, Matthew B. Yurgelun, James J. Farrell, Amitabh Chak, Elena M. Stoffel, et al.

    Background: Pancreatic surveillance commonly detects pancreatic cysts, most of which are presumed intraductal papillary mucinous neoplasms (IPMN). FUT2, the gene responsible for secretor status, has been implicated in IPMN development, although not with pancreatic cancer risk. Methods: We evaluated the association between inactivating variants in FUT2, FUT3, and ABO and pancreatic cysts in 1,865 patients in the multicenter Cancer of the Pancreas Screening (CAPS) cohort. Multivariable logistic regression was performed to estimate adjusted odds for presumed IPMN prevalence. A Johns Hopkins surgical cohort of 1,582 patients with IPMN, pancreatic ductal adenocarcinoma (PDAC), or carcinoma arising from IPMN was analyzed to examine trend in variant proportion by malignant progression. Results: In the CAPS cohort, older age [OR per year, 1.06 (1.05–1.07); P < 0.001], being FUT2 null [nonsecretors; OR, 1.66 (1.30–2.12); P < 0.001], non-O blood group [OR, 1.31 (1.06–1.62); P = 0.012], having familial-only versus genetic/familial risk [OR, 1.49 (1.20–1.85); P < 0.001], and participating site [OR, 2.20 (1.78–2.73); P < 0.001] were associated with having pancreatic cysts. There were no significant FUT2/ABO-presumed IPMN prevalence interactions. In the combined cohort, the proportion of FUT2-null patients with IPMN without carcinoma (by imaging or pathology) was 319 (27.4%) of 1,162, 57 (24.3% of 234) with IPMN and carcinoma, and 225 (22.5%) of 998 with PDAC alone (P = 0.009 for trend). Conclusions: IPMN is more prevalent in FUT2-null patients under pancreas surveillance, but the increased FUT2-null prevalence is not observed in patients with IPMN with carcinoma. Impact: Pancreatic cancer risk conferred by having IPMN may be lower in FUT2-null compared with FUT2-intact individuals.

  • Open Access

    Supplementary Mats and Methods from A Longitudinal Comprehensive Biospecimen and Clinical Data Repository for Cancer Early Detection: The InAdvance Study

    by Tia L. Kauffman, Elizabeth K. O’DOnnell, Catherine R. Marinac, Ana Babic, Kareem Adams, Jenna B. Beckwith, Tara A. Berman, Kristen D. Brantley, Dipanjan Chowdhury, Brian D. Crompton, et al.

  • Open Access

    Detecting and Preventing Fraudulent Participation in Qualitative Research: Content Analysis of Two Multisite Studies

    by Destiny Harden, Nicolette Rodriguez, Kristi Roybal, Tara Coffin, Gina Johnson, Kelley Le Beaux, Maria Connolly, Jennifer Rountree, Chinedu Ukaegbu, Anna C Revette, et al.

    Background: The use of web-based approaches to identify, recruit, enroll, survey, and interview health-related research participants has increased over time, with rapid acceleration since the COVID-19 pandemic. These approaches can make research more accessible to a broader population, but also increase the risk of fraudulent or imposter participants infiltrating research studies. While this threat has been discussed extensively in quantitative survey research, less has been reported in qualitative and mixed methods studies. Objective: This study aims to identify recurring patterns of fraudulent study participation and to offer strategies for identification, remediation, and reporting. Methods: Encounters with fraudulent or imposter individuals during recruitment, enrollment, survey distribution, data collection, and focus group sessions in 2 multisite qualitative and mixed methods research studies are presented. Content from both studies was analyzed to identify common themes and develop strategies for prevention and remediation. Results: Investigators across 2 multisite studies observed several indicators of suspected fraudulent activity, including large response volumes over a short period, highly repetitive email addresses, higher-than-expected proportions of phone numbers with area codes outside the study area, and unusual email/phone responses using atypical language and phrasing. Several imposter or fraudulent individuals disrupted online focus group sessions. To mitigate these issues, both studies implemented remediation strategies, including enhanced screening procedures at baseline, cross-checking of survey responses, and additional identity verification methods prior to participation. Studies took various actions to address these experiences, including notifying the institutional review board, recruitment platforms, and funders. Conclusions: This multisite study identified multiple ways that imposter or fraudulent participants can pose a significant and evolving threat to the integrity of qualitative and mixed methods. These types of fraudulent actors can distort data and undermine research credibility. Lessons learned highlight the importance of real-time recruitment and enrollment analysis and the need for transparent reporting. Addressing this issue will require a comprehensive approach to prevent and address fraudulent study participation that includes collaboration with multiple stakeholders and the broader research community to effectively address this issue.

  • Open Access

    Supplementary Mats and Methods from A Longitudinal Comprehensive Biospecimen and Clinical Data Repository for Cancer Early Detection: The InAdvance Study

    by Tia L. Kauffman, Elizabeth K. O’DOnnell, Catherine R. Marinac, Ana Babic, Kareem Adams, Jenna B. Beckwith, Tara A. Berman, Kristen D. Brantley, Dipanjan Chowdhury, Brian D. Crompton, et al.

  • Open Access

    Data from A Longitudinal Comprehensive Biospecimen and Clinical Data Repository for Cancer Early Detection: The InAdvance Study

    by Tia L. Kauffman, Elizabeth K. O’DOnnell, Catherine R. Marinac, Ana Babic, Kareem Adams, Jenna B. Beckwith, Tara A. Berman, Kristen D. Brantley, Dipanjan Chowdhury, Brian D. Crompton, et al.

    Background:The InAdvance Study addresses the critical need for comprehensive data and biospecimen collection from individuals at elevated risk for cancer. Despite the existence of numerous biobanks for patients with cancer and individuals at average risk for cancer, a gap persists in resources targeting individuals with an elevated risk for cancer.Methods:The InAdvance Study is longitudinally collecting biospecimens and health data from individuals with a range of cancer risk factors to facilitate collaborative research in cancer early detection and interception. Patient populations include those with precancerous or precursor lesions (e.g., oral precursor lesions and Barrett's esophagus), hereditary cancer risk, personal or family history of cancer, or a history of exposures associated with cancer risk. Additionally, we are enrolling patients receiving multicancer early detection (MCED) tests, family members of elevated risk participants, and controls. Key goals include optimized biospecimen collection through standardized procedures, participant enrollment and engagement through an online platform, and standardized scalable procedures. Data are compiled into a central repository, and researchers can request access through a streamlined data request process.Results:Since April 2023, 1,415 participants have enrolled in the study. In total, 817 (58%) completed the baseline survey, and 816 (58%) gave a baseline blood sample.Conclusions:The InAdvance Study’s comprehensive approach provides a framework for basic, population, and translational studies to elucidate the molecular and environmental factors that drive cancer development.Impact:Comprehensive data and biospecimen biorepositories are critical to informing strategies for early detection, risk stratification, early interception for risk mitigation, and improved outcomes for higher-risk populations.

  • A Longitudinal Comprehensive Biospecimen and Clinical Data Repository for Cancer Early Detection: The InAdvance Study

    by Tia L. Kauffman, Elizabeth K. O’DOnnell, Catherine R. Marinac, Ana Babic, Kareem Adams, Jenna B. Beckwith, Tara A. Berman, Kristen D. Brantley, Dipanjan Chowdhury, Brian D. Crompton, et al.

    Background: The InAdvance Study addresses the critical need for comprehensive data and biospecimen collection from individuals at elevated risk for cancer. Despite the existence of numerous biobanks for patients with cancer and individuals at average risk for cancer, a gap persists in resources targeting individuals with an elevated risk for cancer. Methods: The InAdvance Study is longitudinally collecting biospecimens and health data from individuals with a range of cancer risk factors to facilitate collaborative research in cancer early detection and interception. Patient populations include those with precancerous or precursor lesions (e.g., oral precursor lesions and Barrett's esophagus), hereditary cancer risk, personal or family history of cancer, or a history of exposures associated with cancer risk. Additionally, we are enrolling patients receiving multicancer early detection (MCED) tests, family members of elevated risk participants, and controls. Key goals include optimized biospecimen collection through standardized procedures, participant enrollment and engagement through an online platform, and standardized scalable procedures. Data are compiled into a central repository, and researchers can request access through a streamlined data request process. Results: Since April 2023, 1,415 participants have enrolled in the study. In total, 817 (58%) completed the baseline survey, and 816 (58%) gave a baseline blood sample. Conclusions: The InAdvance Study’s comprehensive approach provides a framework for basic, population, and translational studies to elucidate the molecular and environmental factors that drive cancer development. Impact: Comprehensive data and biospecimen biorepositories are critical to informing strategies for early detection, risk stratification, early interception for risk mitigation, and improved outcomes for higher-risk populations.

  • Open Access

    Supplementary Table 1 from Diagnostic Outcomes among Patients with Positive Multi-Cancer Early Detection Test Results

    by Elizabeth K. O’DOnnell, Tia L. Kauffman, Sydney Asnis, Victoria A. Kelly, Ella Matthews, Matheos Kartsounis, Harita Dharaneeswaran, Jenna B. Beckwith, Ciola Bennett, Marjorie Marto, et al.

    Supplementary Table 1 shows the primary and secondary CSOs from the MCED test and the diagnostic evaluations performed.

  • Open Access

    Supplementary Appendix from Diagnostic Outcomes among Patients with Positive Multi-Cancer Early Detection Test Results

    by Elizabeth K. O’DOnnell, Tia L. Kauffman, Sydney Asnis, Victoria A. Kelly, Ella Matthews, Matheos Kartsounis, Harita Dharaneeswaran, Jenna B. Beckwith, Ciola Bennett, Marjorie Marto, et al.

    Supplementary Appendix shows the referral and diagnostic timelines for the 14 patients presenting with a cancer signal-detected MCED test.

  • Open Access

    Table 1 from Diagnostic Outcomes among Patients with Positive Multi-Cancer Early Detection Test Results

    by Elizabeth K. O’DOnnell, Tia L. Kauffman, Sydney Asnis, Victoria A. Kelly, Ella Matthews, Matheos Kartsounis, Harita Dharaneeswaran, Jenna B. Beckwith, Ciola Bennett, Marjorie Marto, et al.

    Characteristics of adults with cancer signal detected by Grail Galleri Test at DFCI MCEDa Program (n = 14).

  • Open Access

    Supplementary Table 2 from Diagnostic Outcomes among Patients with Positive Multi-Cancer Early Detection Test Results

    by Elizabeth K. O’DOnnell, Tia L. Kauffman, Sydney Asnis, Victoria A. Kelly, Ella Matthews, Matheos Kartsounis, Harita Dharaneeswaran, Jenna B. Beckwith, Ciola Bennett, Marjorie Marto, et al.

    Supplementary Table 2 shows our general approach for performing a clinical evaluation of a patient with a cancer signal-detected test result.